What happens after 30 days on Mounjaro — and what real use looks like

The decision at 30 days: continue, adjust, or raise a concern?

The question most people are really asking at the one-month mark is: should I carry on? Most treatment courses begin at 2.5 mg, a dose chosen specifically to let the body acclimatise rather than to drive weight loss from day one. If you've used Mounjaro for 30 days and feel the effects are subtle, that's expected at this stage. The first pen's job is settling your system. Appetite suppression and the slowing of gastric emptying do happen at 2.5 mg, but the more noticeable changes tend to build as the dose is titrated upward, typically in four-week steps under prescriber guidance.

The decision to continue, pause, or escalate isn't one to make alone. Your prescriber reviews your progress (weight, tolerability, any side effects you've reported) before each repeat supply. That review is the checkpoint. It's also the right moment to raise anything you weren't sure was worth mentioning: a persistent headache, reflux that hasn't settled, or simply wanting to understand what's coming next.

The clinical picture at the 30-day stage looks different for everyone, and that breadth is precisely why a prescriber-led review matters more than an online poll.

What people who have used Mounjaro for a month tend to report

The consistent thread in accounts from people 30 days into Mounjaro is appetite change. Portions that previously felt normal start feeling adequate sooner. Cravings (particularly for highly palatable foods) often feel less insistent. This isn't universal, and it can take longer for some people to notice it, but it's the effect the medicine is designed to produce by slowing gastric emptying and acting on satiety signals via dual GIP and GLP-1 receptor pathways, as described in the NHS patient information for tirzepatide.

Side effects in the first 30 days are usually gastrointestinal: nausea, constipation, loose stools, indigestion, or some combination of these. They tend to peak in the early days after injection and ease across the week. By the end of the first pen, many people find they've largely settled. Those who found the first four weeks rough often report that subsequent doses are easier, once the body has adapted to the mechanism.

What people less commonly report at 30 days: significant visible weight change. A 2–3 kg shift is possible, and welcome, but the trial results that reach 20% body-weight reduction were measured at 72 weeks, not one month. Framing the first 30 days as the foundation rather than the result helps calibrate expectations honestly. If you're unsure whether ongoing use is appropriate once your first pen is finished, our page on whether Mounjaro can be used after 30 days covers the key clinical considerations in detail.

Safety signals worth knowing about after the first pen

Most side effects in the first 30 days are mild and transient. There are a small number that warrant prompt medical attention, and knowing them is part of using the medicine safely. Severe, persistent abdominal pain that reaches through to the back (with or without vomiting) should be assessed urgently, as it can be a sign of pancreatitis. The MHRA highlighted acute pancreatitis as a known, infrequent but serious risk in a Drug Safety Update published in January 2026 for GLP-1 medicines including tirzepatide. Gallbladder symptoms, significant dehydration from vomiting or diarrhoea, and any allergic reaction are also reasons to seek help rather than wait.

Women using oral contraceptives should know that tirzepatide may reduce pill absorption in the first four weeks of treatment and for four weeks after each dose increase, a barrier method during those windows is the recommended approach under NHS guidance. That's a practical detail that sometimes gets missed in the first month.

If you have questions about anything you've experienced, your prescriber is the right starting point. At nume, aftercare support runs seven days a week, our contact page explains how to reach the team.

What comes next, and how the 30-day mark fits into the longer picture

Thirty days in, you're at a decision point that most people on Mounjaro reach: the first repeat. At a regulated UK pharmacy, that means a clinical re-review before any further supply is issued. A prescriber reads your progress, checks tolerability, and decides whether to maintain or increase the dose. That process repeats at each stage of titration, all the way to the licensed maximum of 15 mg if needed and appropriate.

For context, SURMOUNT-1 (the pivotal trial of tirzepatide for weight management) ran for 72 weeks and involved thousands of adults with obesity. Average weight reduction at 15 mg reached around 20–21% of starting body weight. The trajectory was not linear; meaningful change accumulated over months, not weeks. Understanding where 30 days sits on that curve makes the early phase feel less like stagnation and more like a starting point.

Anyone considering starting treatment, or wondering whether they meet the eligibility criteria, can read about whether Mounjaro is suitable for their situation and check their eligibility through a free consultation, reviewed the same day by a GPhC-registered Independent Prescriber. Your first pen arrives via DPD the next working day if approved before 12pm, in plain, unbranded packaging. There's no subscription, and every repeat order goes through the same clinical re-review.